CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Oct. 01, 2022	Jan. 01, 2022
Current assets:
Cash and cash equivalents	$ 63,681	$ 30,490
Patient accounts receivable	219,246	218,917
Receivables under insured programs	6,789	6,373
Prepaid expenses	12,604	14,233
Other current assets	9,764	9,202
Total current assets	312,084	279,215
Property and equipment, net	24,919	31,374
Operating lease right of use assets	53,789	51,992
Goodwill	1,368,333	1,835,580
Intangible assets, net	97,779	102,851
Receivables under insured programs	23,970	25,530
Other long-term assets	92,495	7,829
Total assets	1,973,369	2,334,371
Current liabilities:
Accounts payable and other accrued liabilities	48,960	52,624
Accrued payroll and employee benefits	49,996	54,565
Current portion of insurance reserves - insured programs	6,789	6,373
Current portion of insurance reserves	17,326	13,466
Securitization obligations	140,000	120,000
Current portion of long-term obligations	9,200	8,600
Current portion of operating lease liabilities	12,496	13,534
Current portion of deferred payroll taxes	25,523	25,523
Other current liabilities	41,391	50,146
Total current liabilities	351,681	344,831
Long-term obligations, less current portion	1,282,603	1,226,517
Long-term insurance reserves - insured programs	23,970	25,530
Long-term insurance reserves	37,146	35,122
Operating lease liabilities, less current portion	44,518	44,682
Deferred income taxes	2,753	3,046
Other long-term liabilities	616	16,692
Total liabilities	1,743,287	1,696,420
Commitments and contingencies (Note 10)
Deferred restricted stock units	2,135	2,135
Stockholders’ equity:
Preferred stock, $0.01 par value as of October 1, 2022 and no par value as of January 1, 2022, 5,000,000 shares authorized; none issued or outstanding
Common stock, $0.01 par value, 1,000,000,000 shares authorized; 185,918,240 and 184,732,268 issued and outstanding, respectively	1,859	1,847
Additional paid-in capital	1,225,019	1,208,645
Accumulated deficit	(998,931)	(574,676)
Total stockholders’ equity	227,947	635,816
Total liabilities, deferred restricted stock units, and stockholders’ equity	$ 1,973,369	$ 2,334,371